Skip to content

Ultra Low Dose CT and Use of Iomeron 400 in PCD-CT

Ultra Low Dose CT and Use of Iomeron 400 in PCD-CT

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06360627
Enrollment
100
Registered
2024-04-11
Start date
2023-02-20
Completion date
2027-12-01
Last updated
2024-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer, Lung Embolism, Pneumonia, Radiation Exposure

Brief summary

Evaluation of ultra low dose protocols and Iomeron 400 contrast in PCD-CT

Interventions

RADIATIONComputed Tomography

Computed Tomography CHEST

Sponsors

University of Zurich
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* CT SCAN for pulmonary nodule detection/follow up * CT SCAN for pneumonia detection/follow up

Exclusion criteria

* under 18 * BMI over 30

Design outcomes

Primary

MeasureTime frameDescription
Dose Reduction by new scannerthrough study completion, an average of 1 yearmSv per exam will be recorded. This value will be put in correlation to weight (Kg), height (cm) and BMI.
stable Image Quality in reduced dose scansthrough study completion, an average of 1 yearRecorded values compared in 2 populations-different contrast agents by using qualitative&quantitative methods Qualitative:diagnostic certainty, assessability of lung structure/lesions,diagnostic reliability, Quantitative:Assessment of tissue composition,diagnostic performance measurements Attenuation/sealing measurement (HU), signal-to-noise ratio (SNR), contrast-to-noise ratio ,size dimensions of lung structure/lesion in three dimensions in millimeters Tissue composition assessment diagnostic performance measurements (sensitivity, specificity, accuracy) diagnostic confidence: 1-4 Theses measurements will be put in correlation to the scan dose (mSv) per patient, forming two groups with matched BMI (kg/m\^2)

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026